Integrating the Pharmaceutical Manufacturing Process and...

54
3DS.COM © Dassault Systèmes | Confidential Information | 1/5/2017 | ref.: 3DS_Document_2015 Integrating the Pharmaceutical Manufacturing Process and Quality Organizations to Drive Right First Time Performance Justin O. Neway, Ph.D. Vice President, Process Production Operations Senior Fellow, BIOVIA Science Council BIOVIA, a division of Dassault Systèmes

Transcript of Integrating the Pharmaceutical Manufacturing Process and...

3DS

.CO

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Integrating the Pharmaceutical Manufacturing Process

and Quality Organizations

to Drive Right First Time Performance

Justin O. Neway, Ph.D.

Vice President, Process Production Operations

Senior Fellow, BIOVIA Science Council

BIOVIA, a division of Dassault Systèmes

2

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Presentation Outline Our complex manufacturing process and quality environment

A quick look at:

Data integrity

FDA Guidance on Contractor Quality Agreements

Continued Process Verification (CPV)

Manufacturing Quality Metrics (MQM)

Traditional approaches and barriers

Best practices for Right First Time manufacturing

Example – Collaborative Platform for Right First Time operations

Business benefits

3

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Recent Industry Trends

4

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Shortening Time to Market: 2015 Challenges

LNS Research, 2015

5

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Quality Management: 2015 Challenges

LNS Research, 2015

6

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

The Modern Manufacturing Process and Quality Network

Paper Records

Paper Records

Paper Records

7

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Recent Regulatory Trends

8

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

A Decade of Manufacturing Regulatory InitiativesProcess Analytical Technology (PAT) - 2004

Quality by Design (QbD) - 2006

Continued Process Verification (CPV) - 2011

Contractor Quality Agreements (CQA) - 2013

Manufacturing Quality Metrics (MQM) – 2015/2016

Real-time (on-line, in-line, at-line) control of Quality

Control of Quality is designed into the process

Must continue to monitor in-process and final product Quality for all batches

Sponsor and Contractor (CMO) are both responsible for Quality

Agency requires regular submission of Manufacturing Quality Metrics

9

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015 Influence of Inspections: Data Integrity Findings

A Critical Business and Regulatory Issue

10

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

What is Data Integrity? ALCOA Principles Attributable – Who performed the action and When? If a record was changed,

who did it and why? Link to the source data

Legible – Data must be recorded permanently in a durable medium and be

readable

Contemporaneous – The data should be recorded at the same time as the

work is performed, and date-and-time stamps should follow in order

Original – Is the data the original record or a certified copy?

Accurate – No errors or editing performed without documented amendments

11

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

The Data Integrity Fraud Triangle

Example: Management objectives

that measure number of tests that

pass in a limited time

Example: Falsifier can make entries

or changes without witnesses or

built-in system controls

Example: Falsifier tells themselves that

The change is really minor and may even

save the company in the long run

12

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Influence of Drug Shortage Findings

13

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Reasons for Drug Shortages (2007 – 2013)

14

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015 The Regulatory Response

A Big Focus on Quality and Data Integrity

15

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Continued Process Verification (CPV) Trending

CPV originated with the GMPs (21CFR211.110):

“Such control procedures shall be established to monitor the output and to validate

the performance of those manufacturing processes that may be responsible for

causing variability in the characteristics of in-process material and the drug product.”

Recently highlighted in Stage 3 of the updated FDA Validation Guidelines:

“The goal of the third validation stage is continual assurance that the process

remains in a state of control (the validated state) during commercial manufacture.”

Guidance for Industry, Process Validation: General Principles and Practices, FDA, 2011

16

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

FDA Guidance on Contractor Quality Agreements Because the Agency considers contractors and “extension of the manufacturer’s own facility,”

both Owners and Contracted Facilities are responsible for ensuring that their products are not adulterated or misbranded”

The parties to a Quality agreement should include:

A communication plan about how deviations will be communicated

And how such deviations will be communicated and resolved

Owners and contractors should both be aware and communicate:

Investigations into deviations and OOS results

Stability Studies

Process Capability Analysis and Trending

Process improvement projects

Guidance for Industry: Contract Manufacturing Arrangements for Drugs: Quality Agreements, FDA, May 2013

17

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

FDA Quality Metrics Guidance, November 2016FDA intends to use quality metrics data to:

Establish a signal detection program as one factor in identifying establishments and products that may pose significant risk to consumers

Identify situations in which there may be a risk for drug supply disruption

Improve the effectiveness of establishment inspections

Improve FDA’s evaluation of drug manufacturing and control operations

FDA intends to publish an analysis of the quality metrics data received on the FDA Web site to share what the Agency has learned from the voluntary phase of the reporting program, and how analyzing these data has affected the frequency of CGMP inspections and the ability of the Agency to address potential drug shortage situations.

FDA intends to publish a list of the names of establishments that voluntarily report all or a subset of quality data as described in this guidance (Top Tier, Mid Tier)

This list may be useful to establishments within the pharmaceutical manufacturing industry when selecting contract manufacturers and component suppliers

Submission of Quality Metrics Data: Guidance for Industry (DRAFT), FDA, 2016

18

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

The Manufacturing Quality Metrics and What They Show

Lot Acceptance Rate (LAR):

Is the manufacturing process under control?

Next logical question: Please show your investigation, root cause and correction data

Product Quality Complaint Rate (PQCR):

Is the Quality system working?

Next logical question: Please show your CAPA system and results

Invalidated OOS Rate (IOOSR):

Is the organization attempting to “test until the product passes?”

Next logical question: Please show your QMS, management structure and training records

19

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

The Traditional Approach

to Process and Quality Collaboration

20

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

The Problem with Paper

Records and Spreadsheets

Data on paper records cannot be analyzed

Made available in unvalidated spreadsheets

No automated verification or double entry

Complex and inflexible organization (files, tabs)

Not easily searchable across past performance

Hard to manage in a central electronic location

Often customized by different users

Require second person verification for GMP

21

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

The Current State

UPSTREAMDATA

PURIFICATIONDATA

LIMS DATA(Release,..)

COLLECTION

ContinuousHistorian

Batch Records

UNICORN(Continuous I/O)

Batch Records

Excel Layout File

JMP ScriptSingle Point

Multi point/ Continuous

UNICORN“Evaluate”

Up Mfg Excel~100 variables

Pur. Mfg Excel200 variables

Manual Update

Weekly Data Report(per Product)

Control Charts/ Capability

Multi-Point / ContinuousTrend Overlays

HGS1021 S-3 pH Continuous Trend

6.7

6.8

6.9

7.0

7.1

7.2

7.3

7.4

0 20 40 60 80 100 120 140 160

S-3 Time (hours)

pH

3001001341 (Gold) 3001001768 3001001766 3001001760

HGS1021 ProSep Process 410399 cycle1 29apr10001:10_CIR102 HGS1021 ProSep Process 410399 cycle1 29apr10001:10_AIR121pH HGS1021 ProSep Process 410399 cycle1 29apr10001:10_AIR131UV1 HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_CIR102 HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_AIR121pH HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_AIR131UV1 HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_Logbook HGS1021 ProSep Process 410399 cycle1 29apr10001:10_Logbook

0.0

1.0

2.0

3.0

AU

3.0

4.0

5.0

6.0

7.0

pH

0 200 400 600 800 l

Start

Equ

il

Load

Beg

in

Was

h 1 B

egin

Was

h 2 B

egin

Eluti

on B

egin

Colle

ction

Star

t

Colle

ction

End

Start

Equ

il

Load

Beg

in

Was

h 1 B

egin

Was

h 2 B

egin

Eluti

on B

egin

Colle

ction

Star

t

Colle

ction

End

ChromatogramOverlays

22

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

The Current State

UPSTREAMDATA

PURIFICATIONDATA

LIMS DATA(Release,..)

Weekly Data Report(per Product)

Control Charts/ Capability

Multi-Point / ContinuousTrend Overlays

HGS1021 S-3 pH Continuous Trend

6.7

6.8

6.9

7.0

7.1

7.2

7.3

7.4

0 20 40 60 80 100 120 140 160

S-3 Time (hours)

pH

3001001341 (Gold) 3001001768 3001001766 3001001760

HGS1021 ProSep Process 410399 cycle1 29apr10001:10_CIR102 HGS1021 ProSep Process 410399 cycle1 29apr10001:10_AIR121pH HGS1021 ProSep Process 410399 cycle1 29apr10001:10_AIR131UV1 HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_CIR102 HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_AIR121pH HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_AIR131UV1 HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_Logbook HGS1021 ProSep Process 410399 cycle1 29apr10001:10_Logbook

0.0

1.0

2.0

3.0

AU

3.0

4.0

5.0

6.0

7.0

pH

0 200 400 600 800 l

Start

Equ

il

Load

Beg

in

Was

h 1 B

egin

Was

h 2 B

egin

Eluti

on B

egin

Colle

ction

Star

t

Colle

ction

End

Start

Equ

il

Load

Beg

in

Was

h 1 B

egin

Was

h 2 B

egin

Eluti

on B

egin

Colle

ction

Star

t

Colle

ction

End

ChromatogramOverlays

ContinuousHistorian

Batch Records

UNICORN(Continuous I/O)

Batch Records

Excel Layout File

JMP ScriptSingle Point

Multi point/ Continuous

UNICORN“Evaluate”

Up Mfg Excel~100 variables

Pur. Mfg Excel200 variables

Manual Update

COLLECTION

23

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

The Current State

UPSTREAMDATA

PURIFICATIONDATA

LIMS DATA(Release,..)

Weekly Data Report(per Product)

Control Charts/ Capability

Multi-Point / ContinuousTrend Overlays

HGS1021 S-3 pH Continuous Trend

6.7

6.8

6.9

7.0

7.1

7.2

7.3

7.4

0 20 40 60 80 100 120 140 160

S-3 Time (hours)

pH

3001001341 (Gold) 3001001768 3001001766 3001001760

HGS1021 ProSep Process 410399 cycle1 29apr10001:10_CIR102 HGS1021 ProSep Process 410399 cycle1 29apr10001:10_AIR121pH HGS1021 ProSep Process 410399 cycle1 29apr10001:10_AIR131UV1 HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_CIR102 HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_AIR121pH HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_AIR131UV1 HGS1021 ProSep Process 410401 CYCLE1 06MAY10001:10_Logbook HGS1021 ProSep Process 410399 cycle1 29apr10001:10_Logbook

0.0

1.0

2.0

3.0

AU

3.0

4.0

5.0

6.0

7.0

pH

0 200 400 600 800 l

Start

Equ

il

Load

Beg

in

Was

h 1 B

egin

Was

h 2 B

egin

Eluti

on B

egin

Colle

ction

Star

t

Colle

ction

End

Start

Equ

il

Load

Beg

in

Was

h 1 B

egin

Was

h 2 B

egin

Eluti

on B

egin

Colle

ction

Star

t

Colle

ction

End

ChromatogramOverlays

ContinuousHistorian

Batch Records

UNICORN(Continuous I/O)

Batch Records

Excel Layout File

JMP ScriptSingle Point

Multi point/ Continuous

UNICORN“Evaluate”

Up Mfg Excel~100 variables

Pur. Mfg Excel200 variables

Manual Update

COLLECTION

24

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Spreadsheet Error Rates

25

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

What do We Really Want?

26

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Digital Collaboration for “Right-First-Time” Performance

Make Safe and Efficacious Products• Short Process Development & Start-up

• Fast Prep & Approval of CMC filings

• High Yield and Quality

• Low Process and Product Variability• Acceptable Process Economics

• Sustainable Supply Chain

AND all the Supporting Data, Information and

Institutionalized Knowledge

Regardless of Organizations or Geographies

Process Development

Manufacturing

Quality

Collaboration

27

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

What are the Barriers?

28

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

ERP LIMS HIST CAPA MES other

The Manufacturing Data Collection Landscape

Paper

Records

Raw MaterialsProcess Step 1

ProcessStep 2

ProcessStep 3

Process Steps…

Final Product

29

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Contextualization – The Biggest Time Sink

Contextualization is the organization of related (linked) data

elements to enable a particular analysis and interpretation

Data plus metadata provides context that allows meaningful

analysis and interpretation

30

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Contextualization: Linking Data and MetadataAnalysis question: What’s happening?

31

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Contextualization – What we do in Spreadsheets

Contextualization is the organization of related data elements to enable a

particular analysis and interpretation

Examples of useful contexts for Process and Quality data analysis:

Data type context: enables specific types of data analyses

Batch context: enables batch-to-batch analyses

Residence time/volume: enables analyses in continuous manufacturing

Process context: enables process-to-process analyses

Site context: enables site-to-site analyses

Genealogy context: enables upstream / downstream correlations

32

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Best Practices for

Right First Time Manufacturing

33

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

ERP Other HIST

Process and Quality Collaboration with BIOVIA Discoverant

InVisionInformation Authoring Environment

KnowledgeNet Information Visualization Environment

Ad Hoc Numerical Analysis, Statistical Modeling,

Visualization and Results Automation

Results can also be displayed in

External Applications

SharePoint, Dashboards,

Word, Crystal Reports

Data is also Available

to External

Applications

Pipeline Pilot, JMP,

Minitab, Umetrics,

MATLAB

Outputs to role-based Dashboards, Portals, Smartphones, etc.

PRIMR for Paper Record Data

Direct ConnectsOracle, jdbc, OPC-HDA, Web Services

Nexus: Data Access, Aggregation & Contextualization

Paper Data Capture Process Databases and Data Warehouses

EBR LIMS CAPA ELN LES

34

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

ERP LIMS HIST CAPA MES other

The Manufacturing Data Collection Landscape

Raw MaterialsProcess Step 1

ProcessStep 2

ProcessStep 3

Process Steps…

Final Product

Paper

Records

Data Access, Aggregation & Contextualization

35

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

What You Didn’t Have to Do to Understand Your Process

ERP

LIMS

HIST

CAPA

MES

other

Paper

Records

other

other

36

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Spreadsheet Error Rates

37

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Collaborating Across Manufacturing

Process and Quality Organizations

38

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Process Development

AND

Technical Operations

Process Sciences

Process Development

AND

Technical Operations

Process Sciences

Collaborative Business Value

Annotate, Index, Search, Collaborate

39

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Collaborative Business ValueTechnical Operations and Process Sciences

Create Analytical Results Outputs

40

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Collaborative Business Value

Annotate, Index, Search, Collaborate

Shop Floor

Plant Operator

41

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Collaborative Business Value

Annotate, Index, Search, Collaborate

Lab Tech

Quality

42

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Collaborative Business Value

Annotate, Index, Search, Collaborate

Supervisor

Plant Manager

43

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Collaborative Business Value

Annotate, Index, Search, Collaborate

Ops Exec

44

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Collaborative Business Value

Annotate, Index, Search, Collaborate

Process Scientists Process Scientists

Executives

Lab TechsOperators

Managers

Site 1

Geography A

Site 2

Geography B

45

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015 Example: Collaboration for Tech Transfer,

Process Improvement, Trusted Reports,

and Submissions

46

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Pharma/Biotech Lifecycle: Overview

Clinical Batch & Clinical Trial

Process Development

Manufacturing Monitoring

SustainableOperations

GTM

Discovery

R&D Batch

Pre-Clinical Batch

Delivery System

Submission to Agencies

Tech Transfer to Manufacturing Operations

Approval to Manufacturing & Marketing

47

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

The Manufacturing Process and Quality Enterprise

Clinical Batch & Clinical Trial

Process Development

Manufacturing Monitoring

SustainableOperations

GTM

Discovery

R&D Batch

Pre-Clinical Batch

Delivery System

Submission to Agencies

Tech Transfer to Manufacturing

Operations

Approval to Manufacturing &

MarketingPaper Records

48

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Paper Records

Self-Service Data with Automated Context

Clinical Batch & Clinical Trial

Process Development

Manufacturing Monitoring

SustainableOperations

GTM

Discovery

R&D Batch

Pre-Clinical Batch

Delivery System

Submission to Agencies

Tech Transfer to Manufacturing

Operations

Approval to Manufacturing &

Marketing

49

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Prepare Reports and Submissions Efficiently

Paper Records

Clinical Batch & Clinical Trial

Process Development

Manufacturing Monitoring

SustainableOperations

GTM

Discovery

R&D Batch

Pre-Clinical Batch

Delivery System

Submission to Agencies

Tech Transfer to Manufacturing

Operations

Approval to Manufacturing &

Marketing

DRDeviation

Report

CAPACorrective and

Preventive Action

APQRAnnual Product

Quality Review

INDInvestigational

New Drug

Application

eCTDCommon

Technical

Document

SUPACScale-up and

Post-approval

Changes

MQMRManufacturing

Quality Metrics

Report

50

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Business Benefits

51

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

18% Reduction

Development Studies

Mission criticalfor Product Launch

Tech Transfer Time Reduction

15% Improvement

Site Productivity

87% reduction

Materials Use

95% Reduction

Data Aggregation Time

Process Design Process ImprovementProcess Performance

52

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Batch failures

$20M/year reduction

Batch processing

16% time reduction

Pharma C

Process performance review

90% time reduction

FDA on-site inspection

50% time reduction

Process Design Process ImprovementProcess Performance

53

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Cost of recalls

$3.7M/product/year

Batch deviation

$35M/year

Root cause investigation

1 month1 hour

90%Hypotheses eliminated

in 1 meeting

instead of 3 weeks

Pharma BPharma A

Process Design Process ImprovementProcess Performance

54

3DS

.CO

M/B

IOV

IA ©

Das

saul

tSys

tèm

es| C

onfid

entia

l Inf

orm

atio

n | 1

/5/2

017

| ref

.: 3D

S_D

ocum

ent_

2015

Questions?

Discussion?